Matria Mashed Again

Matria (MATR Quote) is turning into a chronic pain for shareholders.

The company, which manages the treatment of long-term illnesses, punished investors Thursday with its second weak forecast in two months. The company slashed its aggressive full-year targets, sending shares down 18%.

Matria maintained its recently lowered second-quarter forecast, but cut full-year revenue guidance to between $337 million and $341 million. Wall Street analysts had been banking on revenue of $361 million. Matria's new full-year profit target of $1.10 to $1.17 share looks to come in at the low end of Wall Street expectations even before stock-option expenses have been subtracted.

Matria blamed a big recent acquisition. ...